Glutamate-induced depression of EPSP-spike coupling in rat hippocampal CA1 neurons and modulation by adenosine receptors

Eur J Neurosci. 2010 Apr;31(7):1208-18. doi: 10.1111/j.1460-9568.2010.07157.x. Epub 2010 Mar 19.

Abstract

The presence of high concentrations of glutamate in the extracellular fluid following brain trauma or ischaemia may contribute substantially to subsequent impairments of neuronal function. In this study, glutamate was applied to hippocampal slices for several minutes, producing over-depolarization, which was reflected in an initial loss of evoked population potential size in the CA1 region. Orthodromic population spikes recovered only partially over the following 60 min, whereas antidromic spikes and excitatory postsynaptic potentials (EPSPs) showed greater recovery, implying a change in EPSP-spike coupling (E-S coupling), which was confirmed by intracellular recording from CA1 pyramidal cells. The recovery of EPSPs was enhanced further by dizocilpine, suggesting that the long-lasting glutamate-induced change in E-S coupling involves NMDA receptors. This was supported by experiments showing that when isolated NMDA-receptor-mediated EPSPs were studied in isolation, there was only partial recovery following glutamate, unlike the composite EPSPs. The recovery of orthodromic population spikes and NMDA-receptor-mediated EPSPs following glutamate was enhanced by the adenosine A1 receptor blocker DPCPX, the A2A receptor antagonist SCH58261 or adenosine deaminase, associated with a loss of restoration to normal of the glutamate-induced E-S depression. The results indicate that the long-lasting depression of neuronal excitability following recovery from glutamate is associated with a depression of E-S coupling. This effect is partly dependent on activation of NMDA receptors, which modify adenosine release or the sensitivity of adenosine receptors. The results may have implications for the use of A1 and A2A receptor ligands as cognitive enhancers or neuroprotectants.

MeSH terms

  • Adenosine A1 Receptor Antagonists
  • Adenosine Deaminase / pharmacology
  • Animals
  • CA1 Region, Hippocampal / cytology*
  • Drug Interactions
  • Excitatory Amino Acid Agents / pharmacology
  • Excitatory Postsynaptic Potentials / drug effects*
  • Excitatory Postsynaptic Potentials / physiology
  • Glutamic Acid / pharmacology*
  • In Vitro Techniques
  • Male
  • Neural Inhibition / drug effects
  • Neural Inhibition / physiology*
  • Neurons / drug effects*
  • Neurons / physiology
  • Neuroprotective Agents / pharmacology
  • Probability
  • Pyrimidines / pharmacology
  • Rats
  • Rats, Wistar
  • Receptor, Adenosine A1 / metabolism*
  • Receptors, N-Methyl-D-Aspartate / metabolism
  • Triazoles / pharmacology
  • Xanthines / pharmacology

Substances

  • 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
  • Adenosine A1 Receptor Antagonists
  • Excitatory Amino Acid Agents
  • Neuroprotective Agents
  • Pyrimidines
  • Receptor, Adenosine A1
  • Receptors, N-Methyl-D-Aspartate
  • Triazoles
  • Xanthines
  • Glutamic Acid
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Adenosine Deaminase